Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia.
Orally disintegrating olanzapine is a recently marketed form of olanzapine that dissolves rapidly on contact with saliva. We describe six demented patients resistant to treatment with common oral antipsychotic medications who were successfully treated with the formulation. The importance of these case reports is to make physicians aware that orally disintegrating olanzapine may be useful for the management of psychobehavioral disturbances in demented patients who resist or have difficulty taking standard oral medications.
Reeves
Roy R
RR
Department of Psychiatry, University of Mississippi School of Medicine, Jackson, MS, USA. roy.reeves@med.va.gov
Torres
Rafael A
RA
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000097:blood / Q000188:drug therapy*; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001569:Benzodiazepines; D001682:Biological Availability; D020208:Brain Injury, Chronic / Q000097:blood / Q000188:drug therapy*; D003704:Dementia / Q000097:blood / Q000188:drug therapy*; D015140:Dementia, Vascular / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000097:blood / Q000188:drug therapy*; D008609:Mental Status Schedule; D000077152:Olanzapine; D010890:Pirenzepine / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D011618:Psychotic Disorders / Q000097:blood / Q000188:drug therapy*; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine